|
|
Article: Aldagen Eyes Public Markets to Fund Two Phase III Efforts.
- Article from:
- BIOWORLD Today
- Article date:
- October 30, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
With Phase III testing for two lead programs ahead and partnering discussions under way, Aldagen Inc. has renewed its efforts to go public with an $80.5 million IPO.
The Durham, N.C.-based stem cell firm originally filed for an IPO last year, but later withdraw the filing. Wednesday it filed anew with the Securities and Exchange Commission, not specifying the number of shares or pricing, but pegging the amount it hopes to raise at $80.5 million.
Aldagen has two Phase III programs in progress, ALD-301 which involves using adult stem cells in patients with advanced limb ischemia.
In August the firm reached agreement with the FDA on a special ...